RESUMO
BACKGROUND & AIM: Congestive heart failure (CHF) and anemia were reported to affect resting energy expenditure (REE). The aim of this study was to evaluate the effect of the correction of anemia on REE in subjects with CHF. PATIENTS AND METHODS: Nine anemic patients with compensated CHF and CRF were studied before and after correction of anemia. REE was studied by an open circuit indirect calorimeter, body composition by dual-energy-X-ray absorption and total body and extracellular water by multi-frequency bioelectrical impedence. Four anemic and 5 non-anemic CHF patients who did not receive any new treatment served as controls. RESULTS: After the correction of their anemia patients tended to increase weight (P<0.06), but no significant changes were observed in body composition. Daily caloric intake increased significantly (P<0.02). Ejection fraction increased (P<0.05) and pulse rate decreased significantly (P<0.001). REE and REEPP were in the normal range before correction but increased significantly afterwards (1402+/-256 vs. 1496+/-206 kcal/d, and 101+/-9 vs. 109+/-8, P<0.023 and P<0.006, respectively). CONCLUSION: Correction of anemia in patients with CHF increases their REE. This can be related either to improved tissue oxygenation and/or to increased caloric intake.
Assuntos
Anemia/metabolismo , Metabolismo Basal/fisiologia , Composição Corporal/fisiologia , Ingestão de Energia , Insuficiência Cardíaca/metabolismo , Idoso , Idoso de 80 Anos ou mais , Anemia/complicações , Anemia/terapia , Calorimetria Indireta , Impedância Elétrica , Eritropoetina/uso terapêutico , Feminino , Insuficiência Cardíaca/complicações , Humanos , Ferro/administração & dosagem , Ferro/uso terapêutico , Masculino , Pessoa de Meia-Idade , Consumo de Oxigênio , Aumento de PesoRESUMO
Diuretics in low doses are very effective agents for controlling hypertension either where used alone or in combination. They have a marked cardioprotective effect, are the best tolerated of any anti-hypertensives and are at the same time the least expensive.
Assuntos
Anti-Hipertensivos , Hidroclorotiazida , Hipertensão/tratamento farmacológico , Inibidores de Simportadores de Cloreto de Sódio , Anti-Hipertensivos/efeitos adversos , Anti-Hipertensivos/economia , Anti-Hipertensivos/uso terapêutico , Diuréticos , Relação Dose-Resposta a Droga , Humanos , Hidroclorotiazida/efeitos adversos , Hidroclorotiazida/economia , Hidroclorotiazida/uso terapêutico , Risco , Inibidores de Simportadores de Cloreto de Sódio/efeitos adversos , Inibidores de Simportadores de Cloreto de Sódio/economia , Inibidores de Simportadores de Cloreto de Sódio/uso terapêuticoRESUMO
Chronic dialysis is available in Israel to almost all patients who require it. During the last four years the mean number of new patients/million population per year was 44.5 (range, 39.5 to 48.6), excluding patients with systemic diseases such as diabetes mellitus and lupus erythematosus. This number is close to that estimated in a previous study--53/million per year for the years 1965-66--and the discrepancy is probably methodological in nature. The stage of equilibrium for Israel, when the net gain in patients per year approaches zero, as forecast by the European Dialysis and Transplant Association, will be reached in 1983 with 261 dialysis patients/million population. At present, the number is about 171. Inadequately treated hypertension was found to considerably affect long-term survival.